South AfricaGeneric lenacapavir is expected to cost $40 a year, not $28,218.
It opens supply to 120 low- and middle-income countries, where demand outstrips Gilead’s supply.
India’s Dr. Reddy’s Laboratories makes it under a Unitaid-brokered deal, and US Food and Drug Administration approval can speed other countries’ sign-off.
The approval is tentative, and generics from the other licensed makers still await it.
Generic doses could reach some countries within weeks, partners say, but others require national approval first.
How each outlet framed it
drawn from 90+ reports worldwide
- CBC News leans favorable
- frames the $40/year generic lenacapavir price as the same as daily pills, but argues the twice-yearly shot removes the adherence failure
Sources: CBC News